Related Experiment Video
Updated: May 7, 2025
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
Adenosine A1 and A3 Receptors: Distinct Cardioprotection
Bruce T Liang1, Douglas Stewart1, Kenneth A Jacobson2
1Department of Medicine, Cardiovascular Division, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania.
Insights
Adenosine protects the heart during ischemia, but its mechanism is unclear. Recent research on adenosine receptor ligands and cardiac models reveals its cardioprotective signaling pathways.
Area of Science:
- Cardiovascular Physiology
- Molecular Pharmacology
- Cardiac Ischemia
Background:
- Adenosine is released during myocardial ischemia, offering cardioprotection.
- The precise mechanisms underlying adenosine's anti-ischemic effects are not fully understood.
Purpose of the Study:
- To review recent advances in cellular and molecular mechanisms of adenosine's cardiac actions.
- To highlight the cardioprotective effects of novel adenosine receptor ligands.
Main Methods:
- Review of recent scientific literature on adenosine signaling in the cardiovascular system.
- Analysis of data from model systems investigating cardiac adenosine actions.
- Examination of novel adenosine receptor ligands and their pharmacological properties.
Main Results:
- Advances in adenosine receptor ligand chemistry and pharmacology offer new insights.
- Model systems have elucidated signaling cascades from receptor activation to cardioprotection.
- Novel ligands demonstrate significant cardioprotective effects.
Conclusions:
- Understanding adenosine's cellular and molecular mechanisms is crucial for developing new cardioprotective strategies.
- Novel adenosine ligands represent a promising therapeutic avenue for myocardial ischemia.
Abstract:
Adenosine is released in large amounts during myocardial ischemia and exerts potent cardioprotective effects in the heart. Although these observations on adenosine have been known for a long time, how adenosine acts to achieve its antiischemic effect remains incompletely understood. Recent advances in the chemistry and pharmacology of adenosine receptor ligands have provided important and novel information on the function of adenosine receptor subtypes in the cardiovascular system. The development of model systems for the cardiac actions of adenosine has yielded important insights into its mechanism of action and have begun to elucidate the sequence of signaling events from receptor activation to the actual exertion of its cardioprotective effect. The goal of the current article is to review recent advances on the cellular and molecular mechanisms that mediate the cardiac actions of adenosine and to show the cardioprotective effect of novel adenosine ligands.
More Related Videos
Related Concept Videos
01:31Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:30Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
01:26Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...